Emergent Biosolutions, Inc.

EBSNYSE • USD
ThemeBiotech - Drug Development›Infectious Disease & Vaccines
7.63 USD
↘ 0.06 (0.78%)AT CLOSE (11:59 AM EDT)
7.63
↘ 0.00 (0.07%)
POST MARKET (AS OF 04:10 PM EDT)
Post Market
AS OF 04:10 PM EDT
7.63
↘ 0.00 (0.07%)
🟢Market: OPEN

Emergent Biosolutions, Inc. (EBS) trades at $7.84 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest EBS is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jul 17, 2026.

Open?$7.49
High?$7.67
Low?$7.49
Prev. Close?$7.69
Volume?604.3K
Avg. Volume?942.7K
VWAP?$7.59
Rel. Volume?0.64x
Bid / Ask
Bid?$7.45 × 1.0K
Ask?$8.20 × 100
Spread?$0.75
Midpoint?$7.82
Valuation & Ratios
Market Cap?396.8M
Shares Out?51.6M
Float?50.6M
Float %?98.0%
P/E Ratio?N/A
P/B Ratio?0.76
EPS?-$0.17
Dividend?0.00%
Ex-Dividend?N/A
RelatedJNJ
News
Profile
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Themes
Biotech - Drug Development›Infectious Disease & VaccinesDefense & National Security›Defense Supply Chain & Components
Employees
900
Market Cap
396.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.emergentbiosolutions.com
Listed
2006-11-15
Address
300 PROFESSIONAL DR
GAITHERSBURG, MD 20879
Phone: 240-631-3200
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
15
Momentum?
50
Short Sent.?
40
Piotroski F-Score?3/9Weak
Altman Z-Score?1.24Distress
Confidence?68%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?20.28%Squeeze Risk
Short Interest?10.3M
Days to Cover?8.0
Free Float50.6M
Avg Daily Volume1.3M
Settlement Date2026-06-30
Financial Health
Current Ratio?4.28Strong
Quick Ratio?2.08Strong
Cash Ratio?1.08Strong
Debt/Equity?1.10Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.76CHEAP▾
P/S?
Peers
100
S&P
94
0.59CHEAP▾
P/FCF?
Peers
100
S&P
97
2.9CHEAP▾
EV/EBITDA?
Peers
100
S&P
97
4.9CHEAP▾
EV/Sales?
Peers
100
S&P
89
1.20CHEAP▾
Returns & Efficiency
ROE?
Peers
50
S&P
14
-1.6%WEAK▾
ROA?
Peers
50
S&P
6
-0.7%WEAK▾
Cash Flow & Enterprise
FCF?$135.4M
Enterprise Value?$810.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist